BrendanDavidCurtiMD

Medical Oncologist; Robert W. Franz Endowed Chair for Clinical Research, Director Melanoma Program, Cytokine and Adoptive Immunotherapy and Genitourinary Oncology Research and IO Fellowship Providence Health & Services

Join to view full profile

Dr. Curti is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Curti's full profile

Already have an account?

Office
4805 NE Glisan St
11N-1
Portland, OR 97213
Phone+1 530-215-5696

Fax+1 503-215-5695
Is this information wrong?

Education & Training

Georgetown University HospitalFellowship, Medical Oncology, 1988 - 1990
Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 1985 - 1988
Georgetown University School of MedicineClass of 1985

Certifications & Licensure

OR State Medical License 2002 - 2025
PA State Medical License 1986 - 2002
MD State Medical License 1989 - 1998
American Board of Internal Medicine Internal Medicine

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer Start of enrollment: 2005 May 01
Terminated
Phase 2
Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC) Start of enrollment: 2009 Jul 01
Terminated
Phase 2
Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer Start of enrollment: 2010 Jun 01
Withdrawn
Phase 2
A Study of Intratumoral CAVATAK™ in Patients With Stage IIIc and Stage IV Malignant Melanoma (VLA-007 CALM ) Start of enrollment: 2011 Dec 29
Completed
Phase 2
Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer Start of enrollment: 2010 Oct 14
Completed
Phase 1
PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Completed
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma. Start of enrollment: 2011 Jul 01
Active, not recruiting
Phase 2
Stereotactic Radiation and OX40 in Patients With Breast Cancer Metastatic to the Liver or Lung Start of enrollment: 2012 Feb 01
HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma Start of enrollment: 2012 Aug 01
Terminated
Phase 4
Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions Start of enrollment: 2012 Apr 27
Completed
Phase 1
Chemoimmunotherapy and Radiation in Pancreatic Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1
Combination Vaccine Immunotherapy (DRibbles) for Patients With Definitively-Treated Stage III Non-small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
Phase I Study of Safety and Immunogenicity of ADU-623 Start of enrollment: 2014 Jan 08
Completed
Phase 1
Immunoscore in Rectal Cancer Start of enrollment: 2014 Jan 24
Completed
Galectin Inhibitor (GR-MD-02) and Ipilimumab in Patients With Metastatic Melanoma Start of enrollment: 2014 May 08
Completed
Phase 1
α-TEA in Advanced Cancer Start of enrollment: 2014 Aug 04
Completed
Phase 1
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2014 Nov 26
Terminated
Phase 2
A Phase 1 Study to Evaluate MEDI6383 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors Start of enrollment: 2014 Sep 15
Completed
Phase 1
Pilot Study of DRibble Vaccine for Prostate Cancer Patients Start of enrollment: 2014 Oct 24
Completed
Phase 1
A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma Start of enrollment: 2018 Sep 21
Completed
Phase 3
Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients Start of enrollment: 2019 Apr 03
Active, not recruiting
Phase 2
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab Start of enrollment: 2017 Sep 20
Recruiting
Phase 2
Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB/C Melanoma Start of enrollment: 2019 Oct 28
Active, not recruiting
Phase 3
PRO1160 for Advanced Solid and Liquid Tumors (PRO1160-001) Start of enrollment: 2023 Mar 15
Recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

A phase 1 study of triple-targeted therapy with BRAF, MEK, and AKT inhibitors for patients with BRAF-mutated cancers.
Algazi, A., Moon, J., Lao, C., Chmielowski, B., Kendra, K., Lewis, K., Gonzalez, R., Kim, K., Godwin, J., Curti, B., Latkovic-Taber, M., Lomeli, S., Gufford, B., Scump...> ;Cancer. 2024 Jan 23
Regulation of human and mouse bystander T cell activation responses by PD-1.
Catherine T Le, Logan V Vick, Craig Collins, Cordelia Dunai, Michael K Sheng, Lam T Khuat, Isabel Barao, Sean J Judge, Ethan G Aguilar, Brendan Curti, Maneesh Dave, Da...> ;JCI Insight. 2023 Sep 22
3 citations
SALVO: Single-Arm Trial of Ipilimumab and Nivolumab as Adjuvant Therapy for Resected Mucosal Melanoma.
Lisa A Kottschade, Gregory Russell Pond, Anthony J Olszanski, Yousef Zakharia, Evidio Domingo-Musibay, Ralph J Hauke, Brendan D Curti, Sarah Schober, Mohammed M Milhem...> ;Clinical Cancer Research. 2023 Jun 13
3 citations
Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas.
Andrew L Coveler, David C Smith, Tycel Phillips, Brendan D Curti, Sanjay Goel, Amitkumar N Mehta, Timothy M Kuzel, Svetomir N Markovic, Olivier Rixe, David L Bajor, Th...> ;Journal for Immunotherapy of Cancer. 2023 Jun 1
103 citations
Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134.
Atkins, M., Lee, S., Chmielowski, B., Tarhini, A., Cohen, G., Truong, T., Moon, H., Davar, D., O'Rourke, M., Stephenson, J., Curti, B., Urba, W., Brell, J., Funchain, ...> ;Journal of Clinical Oncology. 2023 Jan 10
4 citations
A phase Ib study of interleukin-2 plus pembrolizumab for patients with advanced melanoma.
Ann W Silk, Brendan Curti, Jennifer Bryan, Tracie Saunders, Weichung Shih, Michael P Kane, Phoebe Hannon, Christopher Fountain, Jessica Felcher, Andrew Zloza, Howard L...> ;Frontiers in Oncology. 2023 Jan 1
3 citations
Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembroli...
Charles M Rudin, Hardev S Pandha, Matthew Zibelman, Wallace L Akerley, Kevin J Harrington, Daphne Day, Andrew G Hill, Steven J O'Day, Timothy D Clay, Gavin M Wright, R...> ;Journal for Immunotherapy of Cancer. 2023 Jan 1
5 citations
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study.
Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries, Lynn Feun, Kim A Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Rober...> ;Journal for Immunotherapy of Cancer. 2022 Dec 1
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III tria...
Laurie E McLouth, Yue Zheng, Stephanie Smith, F Stephen Hodi, Uma N Rao, Gary I Cohen, Thomas T Amatruda, Shaker R Dakhil, Brendan D Curti, Ibrahim Nakhoul, Sreenivasa...> ;Quality of Life Research. 2023 Jan 1
2 citations
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.
Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti, Katrina S Pedersen, Todd M Bauer, Stefanie L Groenland, Richard D Carvajal, Vaishali Chhaya, Gray Kirby, Kelly M...> ;Clinical Cancer Research. 2022 Sep 1
1 citations
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma.
Zizhen Feng, Brendan D Curti, David I Quinn, John M Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M Beer, Christopher W Ryan> ;Clinical Genitourinary Cancer. 2022 Oct 1
1 citations
A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy.
Emma Bigelow, Suchi Saria, Brian Piening, Brendan Curti, Alexa Dowdell, Roshanthi Weerasinghe, Carlo Bifulco, Walter Urba, Noam Finkelstein, Elana J Fertig, Alex Baras...> ;Cancer Informatics. 2022 Jan 1
6 citations
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
Craig L. Slingluff, Karl D. Lewis, Robert H.I. Andtbacka, John R. Hyngstrom, Mohammed M. Milhem, Svetomir N. Markovic, Tawnya L. Bowles, Omid Hamid, Leonel Hernandez-A...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
7 citations
Trough levels of ipilimumab in serum as a potential biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab.
Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brendan D. Curti, Walter J. Urba, Brian D. Piening, William L. Redmond> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
273 citations
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Paul C. Nathan, Jessica C. Hassel, Piotr Rutkowski, Jean-François Baurain, Marcus O. Butler, Max Schlaak, Ryan J. Sullivan, Sebastian Ochsenreither, Reinhard Dummer, J...> ;The New England Journal of Medicine. 2021 Sep 23
31 citations
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma.
Robert H.I. Andtbacka, Brendan D. Curti, Gregory A. Daniels, Sigrun Hallmeyer, Eric D. Whitman, Jose Lutzky, Lynn E. Spitler, Karl Zhou, Praveen K. Bommareddy, Mark Gr...> ;Journal of Clinical Oncology. 2021 Aug 31
39 citations
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander I. Spira, Daniel C. Cho...> ;Journal of Clinical Oncology. 2021 Jul 13
82 citations
Recent Advances in the Treatment of Melanoma.
Brendan D. Curti, Mark B. Faries> ;The New England Journal of Medicine. 2021 Jun 9
97 citations
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Amod A. Sarnaik, Omid Hamid, Nikhil I. Khushalani, Karl D. Lewis, Theresa Medina, Harriet M. Kluger, Sajeve Samuel Thomas, Evidio Domingo-Musibay, Anna C. Pavlick, Eri...> ;Journal of Clinical Oncology. 2021 May 12
36 citations
Enhancing clinical and immunological effects of anti-PD-1 with belapectin, a galectin-3 inhibitor.
Brendan D. Curti, Yoshinobu Koguchi, Rom Leidner, Annah S Rolig, Elizabeth Sturgill, Zhaoyu Sun, Yaping Wu, Venkatesh Rajamanickam, Brady Bernard, Ian Hilgart-Martiszu...> ;Journal for Immunotherapy of Cancer. 2021 Apr 1
6 citations
HDAC inhibition prevents transgene expression downregulation and loss-of-function in T-cell-receptor-transduced T cells.
, , , , , , , , , , , , , , , , > ;Molecular Therapy Oncolytics. 2021 Mar 26
84 citations
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Rebekka Duhen, Carmen Ballesteros-Merino, Alexandra K. Frye, Eric Tran, Venkatesh Rajamanickam, Shu-Ching Chang, Yoshinobu Koguchi, Carlo Bifulco, Brady Bernard, Rom L...> ;Nature Communications. 2021 Feb 16
11 citations
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2.
Joseph I. Clark, Brendan Curti, Elizabeth J. Davis, Howard L. Kaufman, Asim Amin, Ajjai Alva, Theodore F. Logan, Ralph J. Hauke, Gerald P Miletello, Ulka N. Vaishampay...> ;Journal of Investigative Medicine. 2021 Feb 4
52 citations
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets
Nina Bhardwaj, Philip Friedlander, Anna C. Pavlick, Marc S. Ernstoff, Brian R. Gastman, Brent A. Hanks, Brendan D. Curti, Mark R. Albertini, Jason J. Luke, Ana Belen B...> ;Nature Cancer. 2020 Nov 16
133 citations
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)
Adi Diab, Nizar M. Tannir, Salah Eddine Bentebibel, Patrick Hwu, Vassiliki A. Papadimitrakopoulou, Cara Haymaker, Harriet M. Kluger, Scott N. Gettinger, Mario Sznol, S...> ;Cancer Discovery. 2020 May 21
Join now to see all

Press Mentions

GALT Stock Increased 25%: Why It HappenedJuly 10th, 2021
Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck CancerJuly 9th, 2021
Nektar Therapeutics Presents New Data from Its Immuno-Oncology Pipeline at the 2020 Society for Immunotherapy of Cancer (SITC) Annual MeetingNovember 11th, 2020
Join now to see all